EGFR and non-small cell lung carcinoma: Owing to a great progress achieved in the targeted therapy of advanced non‐small cell lung carcinoma (NSCLC) patients, harboring candidate driver genes, including epidermal growth factor receptor (EGFR) mutations, and ALK and ROS1 rearrangements, the overall survival (OS) rate has been markedly prolonged.2, 3